Reports Q4 revenue $1.28B, consensus $1.25B. “Underpinning our recent success is a commitment to long-term, profitable growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb (BLCO). “Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Positive Outlook on Bausch + Lomb: Strategic Developments and Acquisition Drive Buy Rating
- BLCO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Bausch Health downgraded at Jefferies with B+L deal catalyst removed
- Bausch + Lomb Ends Sale Exploration, Focuses on Growth Strategies
- Bausch Health board determines not to move forward with Bausch + Lomb sale